Chemotherapy for metastatic breast cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Barni, Sandro ^a   Mandala M ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Advanced; Breast cancer; Chemotherapy; Tailored therapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISOLONE; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG CHOICE; EXPERIMENTAL DESIGN; GENETIC VARIABILITY; HEART FAILURE; HUMAN; MEDICAL DECISION MAKING; METASTASIS; NAUSEA; PHENOTYPIC VARIATION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 30644470280     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi904     Document Type: Article

References (33)

1. Hortobágyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol 1996; 23 (Suppl 11): 1-5.
2. Greenberg P, Hortobágyi G, Smith T et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
3. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomised trials involving 31,150 women. J Clin Oncol 1998; 16: 3439-3460.
4. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In De Vitta VT Jr, Hellman S, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology, 4th edition. Philadelphia, PA: Lippincott Company 1993; 1264-1332.
5. Cardoso F, Di Leo A, Lohrish C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol 2002; 13: 197-207.
6. Sledge GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer (MBC): An Intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592.
7. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
8. Soto C, Reyes S, Delgadillo F et al. Capecitabine (X) plus docetaxel (T) vs Capecitabine plus paclitaxel (P) versus sequential capecitabine the taxane in anthracycline pretreated patients with metastatic breast cancer: Early results (abstract). Proc Am Soc Clin Oncol 2003; 22: 10.
9. Heidemann E, Stoeger H, Souchon R et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002; 13: 1717-1729.
10. The French Epirubicin Study Group (no authors listed). A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9: 305-312.
11. Joensuu H, Holli K, Heikkinen M et al. Combination chemotherapy versus single agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 1998; 16: 3720-3730.
12. Coates A, Gebski V, Bishop JF. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-1495.
13. Muss HB, Case LD, Richards FII et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325(19): 1342-1348.
14. Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-3124.
15. Harris AL, Cantwell BM, Carmichael J. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 1990; 335: 186-190.
16. Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997; 33: 2194-2197.
17. Nooij MA, de Haes JC, Beex LV et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists' preferences. Eur J Cancer 2003; 39: 614-621.
18. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
19. Fumoleau P, Largillier R, Clippe C et al. Multicenter, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
20. Jones S, Winer E, Vogel C. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-2574.
21. Degardin M, Bonneterre J, Hecquet B et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423-426.
22. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-1400.
23. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267-2272.
24. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40.
25. Spielmann M, Llombart-Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303-307.
26. Brodowicz T, Kostler WJ, Moslinger R et al. Single agent gemcitabine as second and third line treatment in metastatic reast cancer. Breast 2000; 9: 338-342.
27. Rha SY, Jeung H, Kim Y et al. Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclitaxel based regimen. Proc Am Soc Clin Oncol 2002;
28. Valerio MR, Cicero G, Armata MG et al. Gemcitabine in pretreated breast cancer. Proc Am Soc Clin Oncol 2001;
29. Smorenburg CH, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001; 66: 83-87.
30. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
31. Keller AM, Mennel RG, Georgoulias VA et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893-3901.
32. Loi S, Desmedt C, Cardoso F, Piccart M, Sotiriou C. Breast cancer gene expression profiling: Clinical trial and practice implications. Pharmacogenomics 2005; 6(1): 49-58.
33. Rudlowski C, Rath W, Becker AJ et al. Trastuzumab and breast cancer. N Engl J Med 2001; 345: 997-998.